Comparison of ¹⁸F Flurodeoxyglucose PET with Ga-67 scintigraphy and conventional imaging modalities in pediatric lymphoma

References

• Gurney J G, Severson R K, Davis S, Robinson L L. Incidence of cancer in children in the United States. Sex-, race- and 1-year age-specific rates by histologic type. Cancer 1995; 75: 2186–2195
   PubMed Web of Science ®Google Scholar
• Philip T, Bergeron C, Frappaz D. Management of paediatric lymphoma. Baillieres Clin Haematol 1996; 9: 769–797
   PubMed Web of Science ®Google Scholar
• DeVita V T, Jr, Canellos G P. The lymphomas. Semin Hematol 1999; 36: 84–94
   PubMed Web of Science ®Google Scholar
• Jochelson M, Mauch P, Balikian J, Rosenthal D, Canellos G. The significance of the residual mediastinal mass in treated Hodgkin's disease. J Clin Oncol 1985; 3: 637–640
   PubMed Web of Science ®Google Scholar
• Bar-Shalom R, Mor M, Yefremov N. The value of Ga-67 scintigraphy and F-18 fluorodeoxyglucose positron emission tomography in staging and monitoring the response of lymphoma to treatment. Sem Nucl Med 2001; 31: 177–190
   PubMed Web of Science ®Google Scholar
• Bekerman C, Hoffer P B, Bitran J D. The role of gallium-67 in the clinical evaluation of cancer. Semin Nucl Med 1984; 14: 296–323
   PubMed Web of Science ®Google Scholar
• Kostakoglu L, Leonard J P, Kuji I, Coleman M, Vallabhajosula S, Goldsmith S J. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomorgraphy and Ga-67 scintigraphy in evaluation of lymphoma. Cancer 2002; 94: 879–888
   PubMed Web of Science ®Google Scholar
• Tan T X, Gelfand M J. Ga-67 scintigraphy in pediatric patients. Comparison of extended SPECT of the chest and abdomen with planar imaging. Clin Nucl Med 1996; 21: 717–719
   PubMed Web of Science ®Google Scholar
• Montravers F, McNamara D, Landman-Parker J, Grahek D, Kerrou K, Younsi N, et al. 18F-FDG in childhood lymphoma: clinical utility and impact on management. Eur J Nucl Med 2002; 29: 1155–1165
   Google Scholar
• Schoder H, Meta J, Yap C, Ariannejad M, Rao J, Phelps M E, et al. Effect of whole-body 18F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med 2001; 42: 1139–1143
   PubMed Web of Science ®Google Scholar
• Hoh C K, Glaspy J, Rosen P, Dahlbom M, Lee S J, Kunkel L, et al. Whole-body PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997; 38: 343–348
   PubMed Web of Science ®Google Scholar
• Buchmann I, Reinhardt M, Elsner K, Bunjes D, Altehoefer C, Finke J, et al. 2(Fluorine-18) fluoro-2-deoxy-d-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 2001; 91: 889–899
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, et al. Prognostic value of positron emission topmography (PET) with fluorine-18 fluoro-deoxyglucose (18F-FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is 18F-FDG-PET a valid alternative to conventional diagnostic methods?. J Clin Oncol 2001; 19: 414–419
   PubMed Web of Science ®Google Scholar
• Tatsumi M, Kitayama H, Sugahara H, Tokita N, Nakamura H, Kanakura Y, et al. Whole-body hybrid PET with 18F-FDG in the staging of non-Hodgkin's lymphoma. J Nucl Med 2001; 42: 601–608
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored Working Group. J Clin Oncol 1999; 17: 1244–1253
   PubMed Web of Science ®Google Scholar
• Israel O, Keidar Z, Bar-Shalom R. Positron emission tomography in the evaluation of lymphoma. Semin Nucl Med 2004; 34: 166–179
   PubMed Web of Science ®Google Scholar
• Friedberg J W, Fischman A, Neuberg D, Kim H, Takvorian T, Ng A K, et al. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma. Leuk Lymphoma 2004; 45: 85–92
   PubMed Web of Science ®Google Scholar
• Mody R, Shulkin B, Yanik G, Hutchinson R, Castle V. PET FDG imaging in pediatric lymphomas. J Nucl Med 2001; 42: 39, Presented at the 48th annual meeting of the Society of Nuclear Medicine, June 24, 2001, Toronto, CA
   Google Scholar
• Bui C, Shulkin B, Mody R, Shreve P D, Strouse P J, Lahti L D. FDG-PET imaging of lymphomas in pediatric patients. Radiology 2002; 225: 285, Presented at the 88th Scientific Assembly and Annual Meeting of RSNA, December 2, 2002, Chicago, IL
   Web of Science ®Google Scholar
• Rini J N, Nunex R, Nichols K, Tonco G G, Tomas M, Hart D, et al. Coincidence-detection FDG-PET versus gallium in children and young adults with newly diagnosed Hodgkin's disease. Pediatr Radiol 2005; 35: 169–178
   PubMed Web of Science ®Google Scholar
• Depas G, DeBarsy C, Jerusalem G, Hoyoux C, Dresse M, Fassotte M, et al. 18F-FDG PET in children with lymphomas. Eur J Nucl Med 2005; 32: 31–38
   Google Scholar
• Kabickova E, Sumerauer D, Cumlivska E, Drahokoupilova E, Nekolna M, Chanova M, et al. Comparison of (18)F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin's disease. Eur J Nucl Med Mol Imaging 2006; 33: 1025–1031
   PubMed Web of Science ®Google Scholar
• Hernandez-Pampaloni M, Takalkar A, Yu J Q, Zhuang H, Alavi A. F-18 FDG-PET imaging and correlation with CT in staging and follow-up of pediatric lymphomas. Pediatr Rad 2006; 36: 524–531
   PubMed Web of Science ®Google Scholar
• Westerterp M, Pruim J, Oyen W, Hoekstra O, Paans A, Visser E, et al. Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters. Eur J Nucl Med Mol Imaging Oct 11, 2006, [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Keyes J W, Jr. SUV: standard uptake or silly useless value?. J Nucl Med 1995; 36: 1836–1839
   PubMed Web of Science ®Google Scholar
• Wirth A, Seymour J F, Hicks R J. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med 2002; 112: 262–268
   PubMed Web of Science ®Google Scholar
• Van den Bossche B, Lambert B, De Winter F. 18-FDG PET versus high-dose Ga-67 scintigraphy for restaging and treatment follow up of lymphoma patients. Nucl Med Commun 2002; 23: 1079–1083
   PubMed Web of Science ®Google Scholar
• Valentin D J. Recalculated dose data for 19 frequently used radiopharmaceuticals from ICRP Publication 53. Ann ICRP 1998; 28: 47–83
   Google Scholar
• Korholz D, Claviez A, Hasenclever D, Kluge R, Hirsch W, Kamprad F, et al. The concept of the GOPH-HD 2003 therapy study for pediatric Hodgkin's disease: evolution in the tradition of the DAL/GPOH studies. Kiln Padiatr 2004; 216: 150–155
   PubMed Web of Science ®Google Scholar
• Korholz D, Kluge R, Wickmann L, Hirsch W, Luders H, Lotz I, et al. Importance of F18-fluorodexoy-d-2-glucose positron emission tomography (FDG-PET) for staging and therapy control of Hodgkin's lymphoma in childhood and adolescence—consequences for the GPOH-HD 2003 protocol. Onkologie 2003; 26: 489–493
   PubMed Web of Science ®Google Scholar
• Hudson M M, Krasin M J, Kaste S C. PET imaging in pediatric Hodgkin's lymphoma. Pediatr Radiol 2004; 34: 190–198
   PubMed Web of Science ®Google Scholar
• Kaste S C, Howard S C, McCarville E B, Krasin M J, Kogos P G, Hudson M M. 18F-FDG avid sites mimicking active disease in pediatric Hodgkin's. Pediatr Radiol 2005; 35: 141–154
   PubMed Web of Science ®Google Scholar